Abnormal MMR results don’t automatically mean Lynch syndrome
Mismatch-repair (MMR) testing looks for signs that a tumor’s DNA-repair system is not working normally; it is a screening result, not a diagnosis of Lynch syndrome. Abnormal results can arise from inherited variants, changes confined to the tumor, or technical and interpretive factors. The distinction matters: the National Cancer Institute estimates that Lynch syndrome accounts for about 3% of colorectal cancers and 2%–3% of endometrial cancers, while many tumors with abnormal MMR findings are not caused by an inherited condition. Understanding what the tests show, why results can be abnormal, and how follow-up testing separates inherited from tumor-only causes helps patients and clinicians choose appropriate care and family counseling.
MMR test results describe tumor repair status, not inherited risk by themselves
Mismatch repair is a cellular system that corrects copying errors in DNA. The principal MMR proteins are MLH1, PMS2, MSH2, and MSH6; they work in pairs, with MLH1 partnering with PMS2 and MSH2 partnering with MSH6. A tumor test may assess whether these proteins are present or whether the tumor has accumulated DNA errors. The National Cancer Institute’s genetics guidance distinguishes tumor screening from germline testing: tumor findings can suggest Lynch syndrome, but establishing an inherited diagnosis generally requires testing DNA from a non-tumor sample and interpreting the result in clinical context.
The term “abnormal MMR” is an umbrella for related findings, not a single result. Common categories include loss of one or more MMR proteins on immunohistochemistry (IHC), high microsatellite instability (MSI-high) on molecular testing, and an unresolved or technically inadequate result. These categories overlap, but they are not interchangeable. A bridge from the tumor-level finding to the inherited-risk question is therefore essential: clinicians use the pattern of loss, tumor type, age, personal and family history, and follow-up tests together.
IHC identifies missing MMR proteins
Immunohistochemistry uses antibodies to show whether MMR proteins are detectable in tumor cells. “Loss” means a protein’s staining is absent in the tumor while appropriate non-tumor cells provide a positive internal control. The pattern can point toward the affected gene pair—for example, loss of MLH1 and PMS2 often leads to evaluation of MLH1, while loss of MSH2 and MSH6 often leads to evaluation of MSH2 or EPCAM. IHC is a useful screening tool, but absent staining does not by itself prove that a person inherited a pathogenic variant.
MSI testing measures instability in repeated DNA sequences
Microsatellites are short, repeated DNA sequences that can become length-variable when MMR repair is impaired. A tumor classified as MSI-high has instability at multiple tested markers; other results may be microsatellite stable or indeterminate. The National Cancer Institute notes that MSI and IHC are widely used to identify tumors that may have defective MMR. Because they measure different features—protein expression versus DNA changes—results can occasionally disagree and may need pathology review or complementary testing.
Abnormal MMR results have inherited and non-inherited explanations
Lynch syndrome is an inherited cancer-predisposition condition caused by a germline pathogenic variant in an MMR-related gene, most often MLH1, MSH2, MSH6, PMS2, or EPCAM. The National Cancer Institute describes Lynch syndrome as an autosomal dominant condition associated with increased risks of colorectal, endometrial, and several other cancers. But a tumor can lose MMR function without a germline variant. This distinction is central to interpreting an abnormal screen and prevents the result from being treated as a hereditary diagnosis before the cause is investigated.
Tumor-only changes can produce an abnormal screen
A tumor may acquire two inactivating changes in an MMR gene during a person’s lifetime. These “double somatic” changes can create the same MMR-deficient pattern seen in Lynch-associated tumors, while remaining limited to the cancer rather than being present throughout the person’s body. In a 2013 study of colorectal and endometrial cancers with suspected Lynch syndrome, Haraldsdottir and colleagues found that a substantial share of cases unexplained by standard germline testing had two somatic MMR mutations. The study illustrates why tumor sequencing can clarify some abnormal results and why the exact proportion depends on the population and testing methods.
MLH1 promoter methylation often explains MLH1/PMS2 loss
When IHC shows loss of MLH1 and PMS2, laboratories commonly test for MLH1 promoter methylation, which can silence the MLH1 gene in tumor cells. In colorectal cancer, BRAF V600E testing may also help distinguish many sporadic MLH1-deficient tumors from Lynch-associated cases; it is not a standalone Lynch test, and its use depends on tumor type and clinical context. NICE guidance recommends tumor testing pathways that include MLH1 promoter hypermethylation analysis, with BRAF testing used in the specified colorectal pathway. A methylated tumor often points to a sporadic cause, but younger age, a striking family history, or other concerning features can still warrant genetics assessment.
Technical and interpretive factors can complicate results
Poor tissue preservation, limited tumor material, weak internal controls, unusual staining, and differences among assays can make a result inconclusive or discordant. A pathology report may therefore recommend repeat testing, review of another tumor block, or a second method. “Abnormal,” “equivocal,” and “failed” are not synonymous: the report’s exact wording and the pattern of protein loss matter. The College of American Pathologists’ guidance on MMR and MSI testing emphasizes validated methods and appropriate interpretation, especially when results may guide treatment as well as hereditary-risk evaluation.
Follow-up testing separates Lynch syndrome from tumor-only MMR deficiency
Once a tumor screen is abnormal, the next step is a structured work-up rather than an assumption. The American College of Gastroenterology recommends evaluating people with abnormal tumor testing for Lynch syndrome and using genetic counseling and germline testing when indicated. The pathway depends on the protein-loss pattern, tumor site, prior tests, and family history. These steps connect a tumor finding to the clinically meaningful question: whether the person and relatives carry an inherited risk.
Germline testing evaluates inherited variants
Germline testing analyzes DNA from blood, saliva, or another non-tumor sample for inherited pathogenic variants. A pathogenic or likely pathogenic variant in an MMR gene or EPCAM can establish Lynch syndrome when interpreted alongside the clinical picture. A “variant of uncertain significance” is not equivalent to a diagnosis and generally should not be used alone to make medical decisions. Pre-test and post-test genetic counseling can explain possible results, implications for relatives, and the limits of testing.
Tumor sequencing can resolve unexplained cases
If germline testing is negative and the tumor remains MMR-deficient without a clear sporadic explanation, paired tumor-normal sequencing or tumor sequencing may identify acquired changes. Finding two somatic hits can support a tumor-only explanation; finding no clear cause leaves residual uncertainty and may prompt specialist review. Results should be interpreted with care because tumor-only testing cannot always determine whether a variant is inherited, and not every assay detects every relevant alteration.
Family history and clinical features still matter
A negative or non-diagnostic test does not erase a concerning personal or family history. Clinicians may consider age at diagnosis, multiple primary cancers, cancer types among relatives, and the age and degree of affected relatives. The U.S. Preventive Services Task Force recommends risk assessment and referral for genetic counseling for people with relevant personal or family histories or ancestry associated with Lynch syndrome. Family-history assessment can therefore identify people who merit evaluation even when tumor screening is unavailable or uninformative.
The distinction changes treatment, surveillance, and family care
MMR status has implications beyond inherited risk. The U.S. Food and Drug Administration has approved immune checkpoint inhibitors for certain cancers with MSI-high or mismatch-repair-deficient features, subject to the specific drug indication and clinical circumstances. Thus, a tumor result may guide treatment even when the cause is sporadic. Conversely, confirming Lynch syndrome can affect surveillance and enable relatives to consider targeted testing and prevention. An abnormal tumor result should therefore be communicated accurately: it can be clinically important without meaning that the patient has Lynch syndrome.
For example, a colorectal tumor with MLH1/PMS2 loss may undergo MLH1 methylation testing. If methylation is present, a sporadic explanation is often more likely; if absent, germline evaluation may follow, especially when personal or family history raises concern. Another patient with MSH2/MSH6 loss and a germline MSH2 pathogenic variant has a different conclusion: Lynch syndrome is confirmed and relatives may be offered cascade testing. These are illustrative pathways, not substitutes for individualized medical advice.
Conclusion: an abnormal MMR screen is a starting point, not a Lynch diagnosis
MMR testing identifies tumors with impaired DNA repair, while Lynch syndrome is an inherited condition that requires evidence of a germline pathogenic variant or a supported clinical diagnosis. IHC and MSI testing flag tumors for further evaluation; MLH1 methylation, selected BRAF testing, germline analysis, and sometimes tumor sequencing help explain why the result is abnormal. Because the answer affects cancer treatment, surveillance, and relatives, patients should review the full pathology report with their oncology team and ask whether genetic counseling or additional testing is appropriate. For further reading, consult the National Cancer Institute’s Lynch syndrome information and current professional testing guidance.
Sources: National Cancer Institute, Genetics of Colorectal Cancer (PDQ), https://www.cancer.gov/types/colorectal/hp/colorectal-genetics-pdq; National Cancer Institute, Genetics of Endometrial Cancer (PDQ), https://www.cancer.gov/types/uterine/hp/endometrial-genetics-pdq; Haraldsdottir S, et al., “Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations,” Gastroenterology, 2014, https://doi.org/10.1053/j.gastro.2013.12.041; National Institute for Health and Care Excellence, Molecular testing strategies for Lynch syndrome in people with colorectal cancer, DG27, https://www.nice.org.uk/guidance/dg27; College of American Pathologists, Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy, https://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/mismatch-repair-and-microsatellite-instability-testing-for-immune-checkpoint-inhibitor-therapy; Syngal S, et al., American College of Gastroenterology, “ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes,” https://pubmed.ncbi.nlm.nih.gov/25645574/; U.S. Preventive Services Task Force, Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer, recommendation statement, https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing; U.S. Food and Drug Administration, FDA approves pembrolizumab for adults and children with unresectable or metastatic, MSI-H or dMMR solid tumors, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adults-and-children-msi-h-or-dmmr-solid-tumors